STAT3 and cancer: As a matter of fact, in a recent study Bose et al. demonstrated that both human and murine PDAC cell lines, expressing high MUC1 levels, are more sensitive to the STAT3 inhibitor Napabucasin compared to cancer cells with low MUC1 expression, confirming the synergistic interaction between MUC1-CT and STAT3 in vitro [64].